Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.68 |
| ▸ | POLB | P06746 | 4/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27605963 | 0.88 | MAPT (0.61) | MAPTPOLBTP53THRBTDP1 | |
| SCHEMBL7171065 | 0.86 | MAPT (0.57) | MAPTPOLBTP53THRBTDP1 | |
| SCHEMBL6259247 | 0.83 | PPARG (0.57) | MAPTPOLBTP53THRBTDP1 | |
| SCHEMBL7622582 | 0.82 | USP2 (0.61) | MAPTTP53KMT2AMEN1USP2 | |
| SCHEMBL6210665 | 0.82 | PPARG (0.54) | MAPTPOLBTP53THRBTDP1 | |
| SCHEMBL6213391 | 0.82 | PPARG (0.54) | MAPTPOLBTP53THRBTDP1 | |
| SCHEMBL6260659 | 0.80 | ESR1 (0.59) | MAPTPOLBTP53THRBTDP1 | |
| SCHEMBL6212239 | 0.78 | POLB (0.50) | MAPTPOLBTP53THRBTDP1 | |
| SCHEMBL17242043 | 0.77 | MAPT (0.68) | MAPTPOLBTP53THRBTDP1 | |
| SCHEMBL6211828 | 0.77 | PPARG (0.52) | MAPTPOLBTP53THRBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | claimed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | claimed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| CN-1537105-A | Quinazolines useful as MMP-13 inhibitors | ��������ʲ��������ι�˾ | 2004-10-13 | — | — | CN | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | MAPT 4823/4885POLB 1104/4885TP53 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.